Kiniksa Announces Preliminary Data from Phase 1 Trial of KPL-404
30 nov. 2020 08h00 HE
|
Kiniksa Pharmaceuticals, Ltd.
- Receptor occupancy and TDAR suppression shown through Day 29 at 3 mg/kg intravenous – - Data to-date support subsequent study in patients, including potential intravenous or subcutaneous monthly...
Kiniksa Reports Third Quarter 2020 Financial Results and Highlights Recent Pipeline and Corporate Activity
05 nov. 2020 07h30 HE
|
Kiniksa Pharmaceuticals, Ltd.
Rilonacept commercial launch in recurrent pericarditis anticipated in 1H 2021, if approved by the FDAMavrilimumab Phase 2 trial in GCA achieved primary and secondary efficacy endpoints with...
Kiniksa Provides Timing of Second Half 2020 Clinical Data Readouts
10 juin 2020 08h00 HE
|
Kiniksa Pharmaceuticals, Ltd.
- Rilonacept pivotal Phase 3 data in recurrent pericarditis expected in Q3 2020 - - Mavrilimumab Phase 2 data in GCA and KPL-404 Phase 1 data expected in Q4 2020 - - Management to provide a...
Kiniksa Reports First Quarter 2020 Financial Results and Highlights Recent Corporate and Pipeline Activity
28 avr. 2020 07h30 HE
|
Kiniksa Pharmaceuticals, Ltd.
– Financial guidance and clinical timelines for rilonacept, mavrilimumab, vixarelimab and KPL-404 remain intact amid COVID-19 pandemic –– Mavrilimumab treatment protocol in COVID-19 pneumonia and...
Kiniksa Reports Third Quarter 2019 Financial Results and Highlights Recent Corporate and Pipeline Activity
28 oct. 2019 16h01 HE
|
Kiniksa Pharmaceuticals, Ltd.
– Clinical data readouts expected throughout 2020 for rilonacept, mavrilimumab, KPL-716 and KPL-404 –– Operating plan funded into 2H 2021; no current plan to raise additional capital prior to...
Kiniksa Reports Second Quarter 2019 Financial Results and Highlights Recent Corporate and Pipeline Activity
12 août 2019 16h02 HE
|
Kiniksa Pharmaceuticals, Ltd.
– Rilonacept pivotal Phase 3 study dosing patients in the U.S., Australia, Israel and Italy; expect to present final Phase 2 data this year – – Mavrilimumab global Phase 2 study dosing patients in...
Kiniksa Reports First Quarter 2019 Financial Results and Highlights Recent Corporate and Pipeline Activity
02 mai 2019 07h30 HE
|
Kiniksa Pharmaceuticals, Ltd.
– First patient dosed in Phase 2a trial of KPL-716 in prurigo nodularis– Upcoming presentations at SID, ISPOR and EULAR scientific conferences on KPL-716, rilonacept and mavrilimumab, respectively–...
Kiniksa to Present KPL-404 Preclinical Data at the Keystone Symposia on Antibodies as Drugs
08 avr. 2019 16h01 HE
|
Kiniksa Pharmaceuticals, Ltd.
HAMILTON, Bermuda, April 08, 2019 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (“Kiniksa”), a biopharmaceutical company focused on discovering, acquiring, developing and...